IPN : €90.36 €0.80 (0.89%) Latest Updates Ipsen continues to strengthen early oncology pipeline with Queen’s University Belfast collaboration and licensing agreement. NEWS Ipsen Pledges Ambitious Action on Climate Change PRESS RELEASES What we do Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience. Therapeutic Areas Oncology Among the top pharmaceutical companies in the world specializing in oncology, we address challenges posed by the most difficult-to-treat cancers. Read more Neuroscience With over 25 years of research, development and commercial experience in neuroscience, we are fully committed to improving health outcomes for patients suffering from debilitating neurological disorders. Read more Rare disease We are committed to developing innovative solutions for people living with rare diseases. By focusing our efforts on these rare conditions, we make substantial impact in areas with significant unmet needs. Read more Consumer Healthcare Our consumer healthcare business brings care and comfort to the daily lives of people around the world with healthcare solutions they can trust. Read more Research and Development As a global biopharmaceutical company with a focus on innovation and specialty care, we have the ambition to build a robust, valuable, and sustainable portfolio of medicines to meet patients and their healthcare teams’ needs. Read more 2020 Integrated Annual Report While facing the challenges presented by COVID-19, Ipsen made great strides in 2020 and announced a new Group strategy under the overarching theme of Focus. Together. For patients & society. This strategy is strongly informed by our commitment to innovate for patient care. Explore Our 2020 Digital Annual Report Careers at Ipsen At Ipsen, we recognize that our employees are the cornerstone of our success. We offer exciting opportunities that will challenge your abilities, grow your career and reward your contribution while making a meaningful difference for patients and society. Search Ipsen positions Partnering We believe that great partnerships create great possibilities. We are on a mission to deliver at least one new molecular entity or meaningful indication each year and collaborations with other like-minded innovators are key for the next phase of our growth. Learn more Investors Visit our dedicated investor section to find more information on financial results, our financial calendar and more. Learn more News Center View all Ipsen continues to strengthen early oncology pipeline with Queen’s University Belfast collaboration and licensing agreement. NEWS Our pledge: industry-leading action for the climate NEWS Rethinking risk factors this Liver Cancer Awareness Month Our company Our Science Our responsibility Patients Partnering Investors News Center Careers Terms & conditions Data privacy Cookie policy Global Privacy Policy © Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021 Your privacy is important to us By clicking “Accept All” , you agree to the storing of cookies on your device to enhance site navigation, measure site performance and show you personalized advertising. You can manage individual cookies preferences or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third-parties intervening on our website, please consult the Cookies Policy, available in the site footer. Cookies settings Reject all Accept all